AURXOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Nuo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.26−0.04 (-3.08%)
Close on Oct 19, 2026
- Market cap
- $60.99M
- P/E (TTM)
- –
- Dividend yield
- –
Nuo Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $4.89M | $3.83M | $3.09M | $2.46M | $1.88M | $1.61M | $1.37M | $1.17M | $1.03M | $782.00K | $608.53K | $485.51K | 94.1% | +161.0% |
| License [Member] | $305.88K | $302.94K | $225.00K | $150.00K | $75.00K | $0 | $0 | – | – | – | – | – | 5.9% | +307.8% |
By region
From the segment and revenue-disaggregation notes of Nuo Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.